Loading...

DBV Technologies S.A.

DBV.PA•EURONEXT
Healthcare
Biotechnology
€1.85
€-0.06(-3.04%)

DBV Technologies S.A. (DBV.PA) Stock Overview

Explore DBV Technologies S.A.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

C+

Score: 58.8/100

Key Financials

Market Cap253.2M
P/E Ratio-1.95
EPS (TTM)$-0.97
ROE-2.68%
Fundamental Analysis

AI Price Forecasts

1 Week$1.33
1 Month$1.10
3 Months$0.87
1 Year Target$0.40

DBV.PA Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of DBV Technologies S.A. (DBV.PA) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of C+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 61.92, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.40.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -1.95 and a market capitalization of 253.2M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

61.92RSI (14)
0.08MACD
27.39ADX
Stats data is not available for DBV.PAStats details for DBV.PA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for DBV.PAAnalyst Recommendations details for DBV.PA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

CEO

Daniel Tassé

Employees

106

Headquarters

177-181 Avenue Pierre Brossolette, Montrouge

Founded

2012

Frequently Asked Questions

;